Clinical focus VAL-083 is a first-in-class small-molecule chemotherapeutic with potential applicability across solid tumors including glioblastoma and non-small cell lung cancer, representing a broad targetable addressable market for oncology physicians and researchers.

Global footprint Company history includes relocation and mergers (Vancouver to San Diego; merger with Adgero Biopharmaceuticals), indicating a broadened access and potential for cross-border collaborations, licensing, or joint development opportunities.

Clinical stage VAL-083 is in U.S. clinical trials for refractory glioblastoma, suggesting opportunities to engage with clinical trial networks, site expansion, patient advocacy groups, and potential early-access discussions for eligible patients.

Financial signals Revenue in the low-to-mid single digits with small employee base implies a lean organization open to partnerships, out-licensing, or co-development agreements to accelerate development and commercialization.

Regulatory potential VAL-083 has approvals in China for lung cancer and CML, plus IND activity for platinum-resistant ovarian cancer, indicating a pathway for regional regulatory collaborations, market expansion, and potential in-licensing deals leveraging existing approvals.